Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
We confirm that all methods for these studies were carried out in accordance with relevant guidelines and regulations, and all experimental protocols satisfy the Adelaide University Human Research Ethics Committee criteria as being negligible risk research
Gehrig SM, van der Poel C, Hoeflich A, Naim T, Lynch GS, Metzger F
Your SheMed clinician can advise on whether your current dose is appropriate to maintain or whether moving up is likely to add meaningful benefit
("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced that China's National Medical Products Administration (NMPA) has approved ecnoglutide injection for glycemic control in adults with type 2 diabetes mellitus (T2DM), making it the world's first approved cAMP-biased GLP-1 receptor agonist
Higher doses (90 mg and 120 mg) achieved up to 12.2% mean reduction from baseline (26.6 lbs) versus 1.3% (2.9 lbs) for placebo, with up to 97% of patients losing 5% of body weight
US$ 20.97
US$ 21.78
US$ 29.06
US$ 26.64
US$ 26.78
US$ 23.38
US$ 21.83
